相似文献
1
PET imaging of tumor growth: not as easy as it looks.
Clin Cancer Res. 2012 Mar 1;18(5):1189-91. doi: 10.1158/1078-0432.CCR-11-3198. Epub 2012 Jan 24.
2
Preliminary F-MRS Study of Tumor Cell Proliferation with 3'-deoxy-3'-fluorothymidine and Its Metabolite (FLT-MP).
Contrast Media Mol Imaging. 2017 Sep 26;2017:3981358. doi: 10.1155/2017/3981358. eCollection 2017.
3
Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
Clin Cancer Res. 2011 Mar 1;17(5):1099-110. doi: 10.1158/1078-0432.CCR-10-1430. Epub 2011 Jan 18.
4
Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-¹⁸F-Fluorothymidine PET and Diffusion-Weighted MR Imaging.
J Nucl Med. 2014 Jun;55(6):983-8. doi: 10.2967/jnumed.113.133348. Epub 2014 Apr 28.
5
Depicting Changes in Tumor Biology in Response to Cetuximab Monotherapy or Combination Therapy by Apoptosis and Proliferation Imaging Using F-ICMT-11 and F-FLT PET.
J Nucl Med. 2018 Oct;59(10):1558-1565. doi: 10.2967/jnumed.118.209304. Epub 2018 May 24.
6
Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3'-deoxy-3'-[¹⁸F]fluorothymidine in preclinical tumor models.
Eur J Nucl Med Mol Imaging. 2011 Aug;38(8):1436-48. doi: 10.1007/s00259-011-1802-4. Epub 2011 Apr 12.
7
Biodistribution and uptake of 3'-deoxy-3'-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model.
J Nucl Med. 2010 Sep;51(9):1447-55. doi: 10.2967/jnumed.110.076356. Epub 2010 Aug 18.
8
PET imaging of proliferation with pyrimidines.
J Nucl Med. 2013 Jun;54(6):903-12. doi: 10.2967/jnumed.112.112201. Epub 2013 May 14.
9
Molecular imaging of proliferation in vivo: positron emission tomography with [18F]fluorothymidine.
Methods. 2009 Jun;48(2):205-15. doi: 10.1016/j.ymeth.2009.03.009. Epub 2009 Mar 24.
10
Effects of capecitabine treatment on the uptake of thymidine analogs using exploratory PET imaging agents: F-FAU, F-FMAU, and F-FLT.
Cancer Imaging. 2016 Oct 17;16(1):34. doi: 10.1186/s40644-016-0092-2.
引用本文的文献
1
F-FLT PET/CT as a Prognostic Imaging Biomarker of Disease-Specific Survival in Patients with Primary Soft-Tissue Sarcoma.
J Nucl Med. 2022 May;63(5):708-712. doi: 10.2967/jnumed.121.262502. Epub 2021 Sep 30.
2
STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [F]FLT PET imaging.
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36). doi: 10.1073/pnas.2105390118.
3
Glioma surveillance imaging: current strategies, shortcomings, challenges and outlook.
BJR Open. 2020 Jun 23;2(1):20200009. doi: 10.1259/bjro.20200009. eCollection 2020.
4
Preclinical Applications of 3'-Deoxy-3'-[F]Fluorothymidine in Oncology - A Systematic Review.
Theranostics. 2017 Jan 1;7(1):40-50. doi: 10.7150/thno.16676. eCollection 2017.
5
Response Monitoring with [F]FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases.
Mol Imaging Biol. 2017 Aug;19(4):540-549. doi: 10.1007/s11307-016-1021-2.
6
Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents.
Front Oncol. 2016 Jul 15;6:152. doi: 10.3389/fonc.2016.00152. eCollection 2016.
7
¹⁸F-FLT and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors.
Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1199-209. doi: 10.1007/s00259-013-2678-2. Epub 2014 Mar 7.
8
Involvement of endoplasmic reticulum stress in capsaicin-induced apoptosis of human pancreatic cancer cells.
Evid Based Complement Alternat Med. 2013;2013:629750. doi: 10.1155/2013/629750. Epub 2013 May 28.
9
Monitoring tumor response with radiolabeled nucleoside analogs in a hepatoma-bearing mouse model early after doxisome(®) treatment.
Mol Imaging Biol. 2013 Jun;15(3):326-35. doi: 10.1007/s11307-012-0604-9.
本文引用的文献
1
[(18)F]FLT-PET imaging does not always "light up" proliferating tumor cells.
Clin Cancer Res. 2012 Mar 1;18(5):1303-12. doi: 10.1158/1078-0432.CCR-11-1433. Epub 2011 Dec 14.
2
Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging.
Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18396-9. doi: 10.1073/pnas.1113045108. Epub 2011 Oct 24.
3
The role of nucleoside/nucleotide transport and metabolism in the uptake and retention of 3'-fluoro-3'-deoxythymidine in human B-lymphoblast cells.
Nucl Med Biol. 2011 Oct;38(7):979-86. doi: 10.1016/j.nucmedbio.2011.03.009. Epub 2011 Jun 22.
4
[18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung.
Clin Cancer Res. 2008 Nov 15;14(22):7423-9. doi: 10.1158/1078-0432.CCR-08-0312.
5
Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas.
J Nucl Med. 2006 Oct;47(10):1612-21.
6
A simplified analysis of [18F]3'-deoxy-3'-fluorothymidine metabolism and retention.
Eur J Nucl Med Mol Imaging. 2005 Nov;32(11):1269-75. doi: 10.1007/s00259-005-1813-0. Epub 2005 Jul 1.
7
Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients.
J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jun 5;820(1):121-30. doi: 10.1016/j.jchromb.2005.03.008. Epub 2005 Apr 19.
8
Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
J Nucl Med. 2003 Sep;44(9):1426-31.
9
2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337.
J Natl Cancer Inst. 2003 May 7;95(9):675-82. doi: 10.1093/jnci/95.9.675.
10
Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells.
J Nucl Med. 2002 Sep;43(9):1210-7.
Zotero 插件